⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BTAI News
BioXcel Therapeutics, Inc. Common Stock
BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering
globenewswire.com
BTAI
BioXcel Therapeutics Announces Approximately $8.0 Million Registered Direct Offering
globenewswire.com
BTAI
BioXcel Therapeutics Announces Positive Phase 2 Topline Results from Columbia University-Led Study of BXCL501 for Treatment of Opioid Withdrawal
globenewswire.com
BTAI
BioXcel Therapeutics to Host Virtual Roundtable Featuring Leading Medical Experts Addressing Latest Developments in Treatment of Acute Agitation in Alzheimer’s Dementia
globenewswire.com
BTAI
BioXcel Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for IGALMI® Label Expansion in the At-Home Setting
globenewswire.com
BTAI
Halper Sadeh LLC Encourages BioXcel Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights
businesswire.com
BTAI
BioXcel Therapeutics Expands Leadership Team to Prepare for Launch of IGALMI® in the At-Home Setting
globenewswire.com
BTAI
BioXcel Therapeutics Planning to Submit sNDA This Month Seeking FDA Approval for At-Home Use of IGALMI®
globenewswire.com
BTAI
Beacon Therapeutics to Present at the 44th Annual JP Morgan Healthcare Conference
globenewswire.com
BTAI
Antibody Optimization Service Market Set to Reach USD 6.07 Billion by 2034, Growing at an 8.45% CAGR Amid Advances in Gene-Editing Technologies
globenewswire.com
ABBV
BMY
GILD
AMGN
AZN
LLY
BIIB
REGN
VRTX
XBI
IBB
CRSP
EDIT
NTLA
ABCL
NVS
MRK
PFE
JNJ
GSK
SNY
BTAI
INSM